Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery
| Autor: | Paulette Mhawech-Fauceglia, Shashrikant Lele, Joshua Kesterson, Susanna Syriac, Nicole Durie |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adenoma
Adult Selective Estrogen Receptor Modulators medicine.medical_specialty Pathology medicine.medical_treatment Broad Ligament Ovary Antineoplastic Agents Breast Neoplasms Polymerase Chain Reaction Piperazines Article Pathology and Forensic Medicine Targeted therapy Metastasis Neoplasms Multiple Primary Biomarkers Tumor Medicine Humans Ovarian Neoplasms business.industry Obstetrics and Gynecology medicine.disease Primary tumor Immunohistochemistry Surgery Radiation therapy Tamoxifen medicine.anatomical_structure Imatinib mesylate Pyrimidines Adnexal Diseases Benzamides Imatinib Mesylate Female Neoplasm Recurrence Local business |
| Zdroj: | International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 30(3) |
| ISSN: | 1538-7151 |
| Popis: | This is the case report of a 38-year-old woman who presented with a mass of the right broad ligament that was diagnosed as a female adnexal tumor of probable Wollfian origin (FATWO). The patient was treated with a simple mass excision. Three years after the excision, the patient presented with uterine bleeding. A total abdominal hysterectomy was advised. Intraoperative histologic consultation showed a poorly differentiated tumor on the surface of the left ovary. After extensive immunohistochemistry analysis and after reviewing the histology slides from the primary tumor, the final diagnosis was concluded to be recurrent FATWO on the surface of the ovary. C-kit immunohistochemistry was found to be strongly positive. Polymerase chain reaction amplification of C-kit genes on exons 9, 11, 13, and 17 and of PDGFR gene on exons 12 and 18 showed no mutational changes. Owing to the limited options in treating recurrent disease and the lack of prognostic factors for recurrence or metastasis, the patient was started on 400 mg of imatinib mesylate therapy for 6 months. In addition, the patient is undergoing continuous follow-up by computed tomographic imaging every 6 months. As chemotherapy and radiation therapy for recurrent or metastatic FATWO are most often unsuccessful, a molecular targeted therapy, such as tyrosine kinase inhibitor, could be considered. However, collective data are needed from multiple centers to determine its effectiveness in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|